secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0001654954-24-010837
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance
--------------------------------------------------------------------------------

- Reverse split effective Aug 20, 2024; shares outstanding drop from ~72.4M to ~1.4M.
- Authorized shares reduced from 1B to 20M; fractional shares are rounded up to whole shares.
- Split intended to raise bid price above $1.00 to meet Nasdaq continued listing requirement.
- New CUSIP 29273B 401; common stock continues trading under NDRA on Nasdaq.
- Board set ratio on Aug 8 after stockholder authorization at Aug 6 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424010837/0001654954-24-010837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424010837/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-010837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer